EyePoint, Inc.
EYPT
Positions held
Your positionsEYPT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $290.09M | Enterprise value | $140.19M | Trailing P/E | — | Forward P/E | -1.25 |
| PEG | — | Price / book | 1.77 | Beta | 1.68 | Dividend yield | 0.00% |
| Revenue growth | -90.5% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -192.1% |
| Profit margin | 0.0% | ROE | -148.7% | ROA | -74.9% | Debt / equity | 0.13 |
| Current ratio | 4.50 | Free cash flow | -$155.01M | Analyst recommendation | buy | Mean target | $25.91 |
| 52w high | $19.11 | 52w low | $3.05 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.5M | $0.7M | $0.6M | $1.0M | $5.3M |
| Op margin | -19207.1% | -12532.5% | -11346.0% | -6420.8% | -1166.8% |
| Net income | -$94.5M | -$84.8M | -$67.6M | -$59.7M | -$59.4M |
| Gross margin | 100.0% | 24.1% | 39.5% | 25.4% | 96.9% |
| Gross profit | $0.5M | $0.2M | $0.2M | $0.2M | $5.2M |
| Operating income | -$97.4M | -$87.2M | -$70.3M | -$62.0M | -$62.2M |
- Revenue -27% vs prior quarter ($0.5M vs $0.7M).
- Gross margin 100% (was 24.1% prior quarter).
- Operating margin compressed to -19207.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | — |
| Op margin | -776.0% | -337.1% | -163.1% | -190.7% | — |
| Net income | -$232M | -$131M | -$70.8M | -$102M | — |
| Gross margin | 93.4% | 91.4% | 89.9% | 79.9% | — |
| Gross profit | $29.3M | $39.6M | $41.4M | $33.1M | — |
| Operating income | -$243M | -$146M | -$75.1M | -$78.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
2026-09-16 · EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-09-06 · Street Calls of the Week
2026-09-04 · EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO
2026-09-02 · Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
2026-09-02 · EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
2026-08-18 · EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says
2026-08-18 · EyePoint’s Duravyu falls short to Eylea in Phase III trial
2026-08-18 · Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
Price (daily)
Full chart · RSI · MACD · patterns